Head to Head Analysis: Meihua International Medical Technologies (NASDAQ:MHUA) versus Anika Therapeutics (NASDAQ:ANIK)

Meihua International Medical Technologies (NASDAQ:MHUA) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Insider and Institutional Ownership

1.2% of Meihua International Medical Technologies shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 66.6% of Meihua International Medical Technologies shares are held by company insiders. Comparatively, 5.9% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Meihua International Medical Technologies has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Earnings & Valuation

This table compares Meihua International Medical Technologies and Anika Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Meihua International Medical Technologies	$103.35 million	0.18	$6.24 million	N/A	N/A
Anika Therapeutics	$166.66 million	2.26	-$82.67 million	($5.65)	-4.50

Meihua International Medical Technologies has higher earnings, but lower revenue than Anika Therapeutics.

Profitability

This table compares Meihua International Medical Technologies and Anika Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Meihua International Medical Technologies	N/A	N/A	N/A
Anika Therapeutics	-49.60%	-2.10%	-1.71%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Meihua International Medical Technologies and Anika Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Meihua International Medical Technologies	0	0	0	0	N/A
Anika Therapeutics	0	1	1	0	2.50

Anika Therapeutics has a consensus target price of $29.50, indicating a potential upside of 16.14%. Given Anika Therapeutics’ higher possible upside, analysts clearly believe Anika Therapeutics is more favorable than Meihua International Medical Technologies.

Summary

Anika Therapeutics beats Meihua International Medical Technologies on 6 of the 11 factors compared between the two stocks.

About Meihua International Medical Technologies

Meihua International Medical Technologies Co., Ltd. engages in the manufacture, sells, and marketing of medical consumables in the People's Republic of China. The company offers class I, II, and III disposable medical devices. Its products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles, as well as electronic pumps. The company also distributes disposable medical devices sourced from other manufacturers to customers in China. In addition, it offers COVID-19 products comprising disposable medical masks. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.

About Anika Therapeutics

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.